Compare NNOX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNOX | TENX |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 71.1M |
| IPO Year | 2019 | 2001 |
| Metric | NNOX | TENX |
|---|---|---|
| Price | $0.64 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $29.67 |
| AVG Volume (30 Days) | 1.3M | ★ 3.9M |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $147.55 | N/A |
| Revenue Next Year | $81.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $1.31 |
| 52 Week High | $4.71 | $19.40 |
| Indicator | NNOX | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 27.10 |
| Support Level | N/A | $1.31 |
| Resistance Level | $0.81 | $2.22 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.00 | 0.32 |
| Stochastic Oscillator | 6.37 | 5.95 |
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.